Stoneridge Investment Partners LLC Takes $2.86 Million Position in Becton, Dickinson and Company $BDX

Key Points

• Stoneridge Investment Partners LLC has acquired a new stake in Becton, Dickinson and Company, purchasing 12,485 shares valued at approximately $2.86 million, making it the firm's 11th largest holding.
• Analyst ratings for Becton, Dickinson and Company are mixed, with Citigroup downgrading the stock from "strong-buy" to "hold," while Wall Street Zen upgraded it from "hold" to "buy."
• Becton, Dickinson and Company reported a quarterly earnings of $3.68 EPS, surpassing estimates, alongside a revenue of $5.51 billion, which is up 10.4% year-over-year.

Stoneridge Investment Partners LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,485 shares of the medical instruments supplier's stock, valued at approximately $2,860,000. Becton, Dickinson and Company comprises 2.4% of Stoneridge Investment Partners LLC's holdings, making the stock its 11th largest position.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. TFB Advisors LLC grew its position in Becton, Dickinson and Company by 11.3% during the first quarter. TFB Advisors LLC now owns 1,546 shares of the medical instruments supplier's stock valued at $354,000 after buying an additional 157 shares during the period. T. Rowe Price Investment Management Inc. grew its position in Becton, Dickinson and Company by 3.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock valued at $2,880,510,000 after buying an additional 448,644 shares during the period. Capital Analysts LLC grew its position in Becton, Dickinson and Company by 8.6% during the first quarter. Capital Analysts LLC now owns 50,816 shares of the medical instruments supplier's stock valued at $11,640,000 after buying an additional 4,035 shares during the period. Humankind Investments LLC grew its position in Becton, Dickinson and Company by 0.8% during the first quarter. Humankind Investments LLC now owns 8,052 shares of the medical instruments supplier's stock valued at $1,844,000 after buying an additional 62 shares during the period. Finally, Credit Agricole S A grew its position in Becton, Dickinson and Company by 6.3% during the first quarter. Credit Agricole S A now owns 109,111 shares of the medical instruments supplier's stock valued at $24,993,000 after buying an additional 6,494 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.

Insider Activity

In other news, Director Claire Fraser sold 863 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the transaction, the director directly owned 23,143 shares in the company, valued at approximately $4,450,398.90. This trade represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,214 shares of company stock worth $579,206. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX stock traded up $2.8730 during trading hours on Friday, reaching $199.5030. The stock had a trading volume of 1,619,788 shares, compared to its average volume of 2,720,196. The stock's fifty day simple moving average is $180.65 and its 200 day simple moving average is $195.60. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The firm has a market capitalization of $57.18 billion, a PE ratio of 35.88, a PEG ratio of 1.47 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same period last year, the business earned $3.50 earnings per share. Becton, Dickinson and Company's revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research reports. Raymond James Financial lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 1st. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price for the company. in a research report on Friday, May 2nd. Finally, Barclays cut their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.